	US 12,245,614 B2
	Use of whey protein micelles for improving insulin profile in diabetic patients
Etienne Pouteau, Santiago (CL); Lionel Jean Rene Bovetto, Lucens (CH); and Catherine Mace, Lausanne (CH)
Assigned to SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
Appl. No. 14/353,188
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
PCT Filed Oct. 19, 2012, PCT No. PCT/EP2012/070717 § 371(c)(1), (2) Date Apr. 21, 2014, PCT Pub. No. WO2013/057232, PCT Pub. Date Apr. 25, 2013.
Claims priority of application No. 11186144 (EP), filed on Oct. 21, 2011.
Prior Publication US 2014/0255544 A1, Sep. 11, 2014
Int. Cl. A23J 1/20 (2006.01); A23C 21/00 (2006.01); A23L 2/52 (2006.01); A23L 2/66 (2006.01); A23L 33/00 (2016.01); A23L 33/19 (2016.01); A61K 35/20 (2006.01)

CPC A23J 1/205 (2013.01) [A23C 21/00 (2013.01); A23L 2/52 (2013.01); A23L 2/66 (2013.01); A23L 33/19 (2016.08); A23L 33/30 (2016.08); A23L 33/40 (2016.08); A61K 35/20 (2013.01); A23V 2002/00 (2013.01); A23V 2200/00 (2013.01)]

3 Claims

1. A method for decreasing plasma postprandial insulin and plasma postprandial glucagon concentration in a human subject, the method comprising administering to the human subject a nutrition composition that is a meal replacement comprising a daily dose of whey protein micelles 30 g dry weight, lipids 11.7 g dry weight, carbohydrates 42.7 g dry weight, and fibers 6.3 g dry weight in,

wherein the meal replacement is a liquid food product, and the meal replacement decreases the plasma postprandial insulin and the plasma postprandial glucagon concentration relative to a composition containing an equal amount of whey protein isolate.